Tag:
ImmunoGen
Latest Headlines
Latest Headlines
Is ImmunoGen overvalued?
The drug delivery company may not be worth the $1.2 billion its investors would believe.
UPDATED: Roche readies for approvals of previously snubbed breast cancer drug
Roche has turned in positive data from a key Phase III study of its blockbuster hopeful T-DM1.
ImmunoGen banks $20M on new antibody cancer drug pact with Lilly
ImmunoGen ( $IMGN ) is pocketing a $20 million upfront payment from Eli Lilly ( $LLY ) after the two biopharma companies inked a collaboration on the development of conjugated antibody treatments for
Roche trial buoys antibody-based delivery of cancer drugs
The antibody-drug conjugate field has had its ups and downs, but lately developers of such therapies--which use targeted antibodies attached to anti-cancer toxins to home in on tumor cells--have been
ImmunoGen touts new drug-delivering antibodies
After forming partnerships with several major pharmas, ImmunoGen wants to boost its pipeline of proprietary antibody-drug conjugates. The Waltham, MA-based biotech ( $IMGN ) carried this message last
Novartis jumps on board ImmunoGen's hot antibody platform
Waltham, MA-based ImmunoGen is rolling out its latest collaboration this morning, banking a rich, $45 million upfront to put its antibody drug conjugate technology to work for Novartis. The company
ImmunoGen collects $67M from public offering
Waltham, MA-based ImmunoGen ( NASDAQ: IMGN ) has snagged a little more than $67 million from a public offering. The cancer drug developer priced 9 million shares at $8 apiece. J.P. Morgan Securities
ImmunoGen bags second $35M deal with Amgen
ImmunoGen today announced its second licensing deal with Amgen in three months. The biotech giant gains rights to ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology, which uses
ImmunoGen, Amgen forge $35M pact on cancer tech
Waltham, MA-based ImmunoGen struck a deal to license its cancer drug development technology to biotech giant Amgen in a deal that could eventually be worth up to $35 million. Only a million dollars
ImmunoGen looks for $39M in stock offering
Massachusetts-based ImmunoGen is offering 5 million shares of its stock at a price of $7.00 per share. The company is hoping to raise a total of $33 million after underwriting discounts, commissions
